Q3UFK8
Gene name |
Frmd8 |
Protein name |
FERM domain-containing protein 8 |
Names |
iRhom tail-associated protein, iTAP |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:67457 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q3UFK8
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q3UFK8-F1 | Predicted | AlphaFoldDB |
33 variants for Q3UFK8
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3389528989 | 2 | E>* | No | EVA | |
| rs3389523895 | 8 | A>T | No | EVA | |
| rs260501612 | 14 | A>V | No | EVA | |
| rs3389468311 | 21 | S>G | No | EVA | |
| rs3389521015 | 21 | S>T | No | EVA | |
| rs3389518875 | 25 | V>M | No | EVA | |
| rs3389519932 | 82 | P>L | No | EVA | |
| rs3389476795 | 100 | Q>H | No | EVA | |
| rs13461043 | 110 | N>D | No | EVA | |
| rs3389468216 | 119 | D>E | No | EVA | |
| rs3389523902 | 139 | I>F | No | EVA | |
| rs36312787 | 140 | H>L | No | EVA | |
| rs3389512048 | 148 | L>I | No | EVA | |
| rs3408970507 | 164 | D>N | No | EVA | |
| rs3389514713 | 180 | L>I | No | EVA | |
| rs3389468300 | 184 | Q>R | No | EVA | |
| rs3389519902 | 188 | P>H | No | EVA | |
| rs215476575 | 190 | A>T | No | EVA | |
| rs249040022 | 191 | C>Y | No | EVA | |
| rs36559106 | 218 | G>S | No | EVA | |
| rs228559653 | 244 | N>D | No | EVA | |
| rs38253571 | 304 | V>I | No | EVA | |
| rs3389476825 | 306 | D>Y | No | EVA | |
| rs3409005362 | 322 | S>* | No | EVA | |
| rs3389514704 | 343 | S>N | No | EVA | |
| rs3389535281 | 346 | T>M | No | EVA | |
| rs3408902890 | 349 | N>T | No | EVA | |
| rs3406972398 | 350 | K>N | No | EVA | |
| rs235883886 | 376 | A>S | No | EVA | |
| rs3389429104 | 436 | K>M | No | EVA | |
| rs3389429108 | 438 | T>P | No | EVA | |
| rs3389514695 | 445 | Q>H | No | EVA | |
| rs3389512895 | 449 | S>N | No | EVA |
No associated diseases with Q3UFK8
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| centriolar satellite | A small (70-100 nm) cytoplasmic granule that contains a number of centrosomal proteins; centriolar satellites traffic toward microtubule minus ends and are enriched near the centrosome. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
No GO annotations of molecular function
| Name | Definition |
|---|---|
| No GO annotations for molecular function |
3 GO annotations of biological process
| Name | Definition |
|---|---|
| negative regulation of canonical Wnt signaling pathway | Any process that decreases the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes. |
| positive regulation of tumor necrosis factor production | Any process that activates or increases the frequency, rate or extent of tumor necrosis factor production. |
| protein localization to plasma membrane | A process in which a protein is transported to, or maintained in, a specific location in the plasma membrane. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MEGAEGNAGQ | PGPAERSHRS | SVSSVGARAA | DVLVYLADDT | VVPLAVENLS | SISAHELHRA |
| 70 | 80 | 90 | 100 | 110 | 120 |
| VREVLQLPDV | ALEAFALWLV | SPLLEVQLKP | KHQPYKLGRQ | WPELLLRFTN | ASDDDVAMDE |
| 130 | 140 | 150 | 160 | 170 | 180 |
| PSLQFRRNVF | FPRRRELQIH | DEEVLRLLYE | EAKGNVLTAR | YPCDLEDCEV | LGGLVCRVQL |
| 190 | 200 | 210 | 220 | 230 | 240 |
| GPYQPGQPAA | CTLREKLDSF | LPAHLCKRGH | GLFAAFRGRG | AKTGPGEQGL | LNAYRQVKEV |
| 250 | 260 | 270 | 280 | 290 | 300 |
| TGNNSEREAT | LGSHYRAYLL | KCHELPFYGC | AFFHGEVDKP | AQGFLHRGGR | KPVTVAISLE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| GVHVIDNREK | HVLLGLRFQE | LSWDHTSPEE | EEPVLWLEFD | GDSEGTPVNK | LLRIYSKQAE |
| 370 | 380 | 390 | 400 | 410 | 420 |
| LMSGLIEYCI | ELSQAAEPTL | SQESASGPHE | APSPSPPPTQ | RPKLRRQGSV | VCSRIQHLST |
| 430 | 440 | 450 | 460 | ||
| IDYVEDGKGI | KRVKPKRTTS | FFSRQLSSSQ | GSYTVVQPTD | DSLEQS |